Related Experiment Videos
[Oral anticoagulation after major hip or knee replacement surgery: a process-driven managerial pharmacoeconomic
T Wilke1, K Neumann, U Klapper
1Institut für Pharmakoökonomie und Arzneimittellogistik, Hochschule Wismar, PF 1210, 23952 Wismar. thomas.wilke@hs-wismar.de
Background:
The thrombin inhibitor dabigatranetexilat is used for prophylaxis of venous thromboembolism after total hip or knee replacement surgery (THR/TKR). Patients can take it orally in hospitals.
Method:
In a managerial pharmacoeconomic analysis of six German acute-care hospitals and six German rehabilitation hospitals, the use of dabigatranetexilat was compared with the use of low-molecular-weight heparins.
Results:
The analysis showed that the new drug led to an economic advantage for an acute-care hospital of 2.43 euro per patient per day. In a rehabilitation hospital, the use of dabigatranetexilat led to an economic advantage of 1.40 euro per patient per day.
Conclusion:
These results have direct implications for drug decisions in hospitals. To demonstrate that fact, the price difference between dabigatranetexilat and low-molecular-weight heparins was derived to lead exactly to their"economic neutrality" from the hospital's point of view.
Related Concept Videos
Venous Thrombosis III: Interprofessional Care
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Peripheral Artery Disease V: Postoperative Nursing Management
Aneurysm IV: Nursing Management
Venous Thrombosis IV: Nursing Management